C-REACTIVE PROTEIN RANDOMIZED TRIALS AS PREDICTORS FOR USEFULNESS OF ASPIRIN v. MI, SUGGESTED BY STUDY; CRP ASSAY STUDY BY BEHRING MAY BE PUBLISHED IN 1998
This article was originally published in The Gray Sheet
Inflammatory markers such as C-reactive protein should be studied in randomized trials for their utility in providing a method of "identifying people for whom aspirin is likely to be more or less effective" for reducing the risk of myocardial infarction, Paul Ridker, MD, Brigham & Women's Hospital, Boston, et al., state in a study published in the April 3 New England Journal of Medicine.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.